Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) EPS (Basic) (2019 - 2025)

Keros Therapeutics filings provide 7 years of EPS (Basic) readings, the most recent being -$0.38 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 66.07% to -$0.38 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.34, a 146.89% increase, with the full-year FY2025 number at $2.34, up 146.8% from a year prior.
  • EPS (Basic) hit -$0.38 in Q4 2025 for Keros Therapeutics, down from -$0.18 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $3.66 in Q1 2025 to a low of -$1.41 in Q3 2024.
  • Median EPS (Basic) over the past 5 years was -$1.06 (2022), compared with a mean of -$0.73.
  • Biggest five-year swings in EPS (Basic): plummeted 266.67% in 2022 and later surged 402.48% in 2025.
  • Keros Therapeutics' EPS (Basic) stood at -$0.3 in 2021, then plummeted by 266.67% to -$1.1 in 2022, then dropped by 21.82% to -$1.34 in 2023, then rose by 16.42% to -$1.12 in 2024, then surged by 66.07% to -$0.38 in 2025.
  • The last three reported values for EPS (Basic) were -$0.38 (Q4 2025), -$0.18 (Q3 2025), and -$0.76 (Q2 2025) per Business Quant data.